Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|HER2 Positive Breast Carcinoma
Interventions: DRUG: Niraparib|DRUG: Trastuzumab
Sponsor: University of Alabama at Birmingham
Collaborators: Translational Breast Cancer Research Consortium|Tesaro, Inc.|Susan G. Komen Breast Cancer Foundation|Breast Cancer Research Foundation of Alabama|VFoundation